Mutanome Engineered RNA Immunotherapy: Towards Patient-Centered Tumor Vaccination

Journal of Immunology Research

Volumn 2015, Issue , 2015, Pages

  Vormehr, Mathias ^a,b   Schrörs, Barbara ^c   Boegel, Sebastian ^c   Löwer, Martin ^c   Türeci, Özlem ^c   Sahin, Ugur ^a,b,c  

^a Research Center for Immunotherapy (FZI)   (Germany)

^b BIONTECH AG   (Germany)

^c UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER VACCINE; MESSENGER RNA VACCINE; RNA VACCINE; UNCLASSIFIED DRUG; MESSENGER RNA; TUMOR ANTIGEN;

CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL SURVIVAL; CLINICAL STUDY; DRUG COST; DRUG DELIVERY SYSTEM; DRUG POTENCY; HUMAN; MUTANOME ENGINEERED RNA IMMUNOTHERAPY; NEXT GENERATION SEQUENCING; PATIENT CARE; REVIEW; RNA IMMUNIZATION; T LYMPHOCYTE; TUMOR CELL; ANIMAL; GENETIC ENGINEERING; GENETICS; GENOME; HIGH THROUGHPUT SEQUENCING; IMMUNOLOGY; IMMUNOTHERAPY; MUTATION; NEOPLASMS;

ANIMALS; ANTIGENS, NEOPLASM; CANCER VACCINES; GENETIC ENGINEERING; GENOME; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; IMMUNOTHERAPY; MUTATION; NEOPLASMS; PATIENT-CENTERED CARE; RNA, MESSENGER;

EID: 84956914529     PISSN: 23148861     EISSN: 23147156     Source Type: Journal    
DOI: 10.1155/2015/595363     Document Type: Review

References (41)

1. L. B. Alexandrov, S. Nik-Zainal, D. C. Wedge, S. A. J. R. Aparicio, S. Behjati, A. V. Biankin et al., "Signatures of mutational processes in human cancer, " Nature, vol. 500, no. 7463, pp. 415-421, 2013.
2. T. Boon and O. Kellermann, "Rejection by syngeneic mice of cell variants obtained by mutagenesis of a malignant teratocarcinoma cell line, " Proceedings of the National Academy of Sciences of the United States of America, vol. 74, no. 1, pp. 272-275, 1977.
3. C. Lurquin, A. Van Pel, B. Mariamé et al., "Structure of the gene of tum-transplantation antigen P91A: themutated exon encodes a peptide recognized with Ld by cytolytic T cells, " Cell, vol. 58, no. 2, pp. 293-303, 1989.
4. NHGRI, Human Genome Project Completion: Frequently Asked Questions, 2010, http://www. genome. gov/11006943.
5. E. C. Hayden, "Technology: the $1, 000 genome, " Nature, vol. 507, no. 7492, pp. 294-295, 2014.
6. J. C. Castle, S. Kreiter, J. Diekmann et al., "Exploiting the mutanome for tumor vaccination, " Cancer Research, vol. 72, no. 5, pp. 1081-1091, 2012.
7. C. M. Britten, H. Singh-Jasuja, B. Flamion et al., "The regulatory landscape for actively personalized cancer immunotherapies, " Nature Biotechnology, vol. 31, no. 10, pp. 880-882, 2013.
8. F. Duan, J. Duitama, S. Al Seesi et al., "Genomic and bioinformatic profiling of mutational neoepitopes reveals new rules to predict anticancer immunogenicity, "The Journal of Experimental Medicine, vol. 211, no. 11, pp. 2231-2248, 2014.
9. M. Yadav, S. Jhunjhunwala, Q. T. Phung et al., "Predicting immunogenic tumourmutations by combiningmass spectrometry and exome sequencing, " Nature, vol. 515, no. 7528, pp. 572-576, 2014.
10. S. P. Haen and H.-G. Rammensee, "The repertoire of human tumor-associated epitopes-identification and selection of antigens and their application in clinical trials, " Current Opinion in Immunology, vol. 25, no. 2, pp. 277-283, 2013.
11. M. M. Gubin, X. Zhang, H. Schuster et al., "Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens, " Nature, vol. 515, no. 7528, pp. 577-581, 2014.
12. S. D. Brown, R. L. Warren, E. A. Gibb et al., "Neo-antigens predicted by tumor genome meta-analysis correlate with increased patient survival, " Genome Research, vol. 24, no. 5, pp. 743-750, 2014.
13. A. Snyder, V. Makarov, T. Merghoub et al., "Genetic basis for clinical response to CTLA-4 blockade in melanoma, " The New England Journal ofMedicine, vol. 371, no. 23, pp. 2189-2199, 2014.
14. N. A. Rizvi, M. D. Hellmann, A. Snyder et al., "Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer, " Science, vol. 348, no. 6230, pp. 124-128, 2015.
15. E. Tran, S. Turcotte, A. Gros et al., "Cancer immunotherapy based on mutation-specific CD4+ T cells in a patient with epithelial cancer, " Science, vol. 344, no. 6184, pp. 641-645, 2014.
16. M. Löwer, B. Y. Renard, J. de Graaf et al., "Confidence-based somatic mutation evaluation and prioritization, " PLoS Computational Biology, vol. 8, no. 9, Article ID e1002714, 2012.
17. M. Nothnagel, A. Herrmann, A. Wolf et al., "Technologyspecific error signatures in the 1000 Genomes Project data, " Human Genetics, vol. 130, no. 4, pp. 505-516, 2011.
18. M. A. Taub, H. C. Bravo, and R. A. Irizarry, "Overcoming bias and systematic errors in next generation sequencing data, " Genome Medicine, vol. 2, no. 12, article 87, 2010.
19. S. Kreiter, M. Vormehr, N. van de Roemer et al., "Mutant MHC class II epitopes drive therapeutic immune responses to cancer, " Nature, vol. 520, no. 7549, pp. 692-696, 2015.
20. T. Schumacher, L. Bunse, S. Pusch et al., "A vaccine targeting mutant IDH1 induces antitumour immunity, " Nature, vol. 512, no. 7514, pp. 324-327, 2014.
21. P. F. Robbins, Y.-C. Lu, M. El-Gamil et al., "Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells, " Nature Medicine, vol. 19, no. 6, pp. 747-752, 2013.
22. B. M. Carreno, V. Magrini, M. Becker-Hapak et al., "A dendritic cell vaccine increases the breadth and diversity of melanoma neoantigen-specific T cells, " Science, vol. 348, no. 6236, pp. 803-808, 2015.
23. N. Van Rooij, M. M. Van Buuren, D. Philips et al., "Tumor exome analysis reveals neoantigen-specific T-cell reactivity in an ipilimumab-responsive melanoma, " Journal of Clinical Oncology, vol. 31, no. 32, pp. e439-e442, 2013.
24. Z. Qin and T. Blankenstein, "CD4+ T cell-mediated tumor rejection involves inhibition of angiogenesis that is dependent on IFNγ receptor expression by nonhematopoietic cells, " Immunity, vol. 12, no. 6, pp. 677-686, 2000.
25. A. L. Bouwer, S. C. Saunderson, F. J. Caldwell et al., "NK cells are required for dendritic cell-based immunotherapy at the time of tumor challenge, "The Journal of Immunology, vol. 192, no. 5, pp. 2514-2521, 2014.
26. S. P. Schoenberger, R. E. Toes, E. I. van der Voort, R. Offringa, and C. J. Melief, "T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions, " Nature, vol. 393, pp. 480-483, 1998.
27. B. Weide, S. Pascolo, B. Scheel et al., "Direct injection of protamine-protected mRNA: results of a phase 1/2 vaccination trial in metastatic melanoma patients, " Journal of Immunotherapy, vol. 32, no. 5, pp. 498-507, 2009.
28. S. M. Rittig, M. Haentschel, K. J. Weimer et al., "Intradermal vaccinations with RNA coding for TAA generate CD8+ and CD4+ immune responses and induce clinical benefit in vaccinated patients, " Molecular Therapy, vol. 19, no. 5, pp. 990-999, 2011.
29. A. Heiser, D. Coleman, J. Dannull et al., "Autologous dendritic cells transfected with prostate-specific antigen RNA stimulate CTL responses against metastatic prostate tumors, " Journal of Clinical Investigation, vol. 109, no. 3, pp. 409-417, 2002.
30. S. Holtkamp, S. Kreiter, A. Selmi et al., "Modification of antigenencoding RNA increases stability, translational efficacy, and Tcell stimulatory capacity of dendritic cells, " Blood, vol. 108, no. 13, pp. 4009-4017, 2006.
31. A. N. Kuhn, M. Diken, S. Kreiter et al., "Phosphorothioate cap analogs increase stability and translational efficiency of RNA vaccines in immature dendritic cells and induce superior immune responses in vivo, " GeneTherapy, vol. 17, no. 8, pp. 961-971, 2010.
32. S. Kreiter, A. Selmi, M. Diken et al., "Increased antigen presentation efficiency by coupling antigens toMHC class I trafficking signals, "The Journal of Immunology, vol. 180, no. 1, pp. 309-318, 2008.
33. U. Sahin, K. Karikó, and O. Türeci, "mRNA-based therapeutics-developing a new class of drugs, " Nature Reviews Drug Discovery, vol. 13, no. 10, pp. 759-780, 2014.
34. M. Hubo, B. Trinschek, F. Kryczanowsky, A. Tuettenberg, K. Steinbrink, and H. Jonuleit, "Costimulatory molecules on immunogenic versus tolerogenic human dendritic cells, " Frontiers in Immunology, vol. 4, article 82, 14 pages, 2013.
35. S. Kreiter, A. Selmi, M. Diken et al., "Intranodal vaccination with naked antigen-encoding RNA elicits potent prophylactic and therapeutic antitumoral immunity, " Cancer Research, vol. 70, no. 22, pp. 9031-9040, 2010.
36. M. Diken, S. Kreiter, A. Selmi et al., "Selective uptake of naked vaccine RNA by dendritic cells is driven by macropinocytosis and abrogated upon DC maturation, " GeneTherapy, vol. 18, no. 7, pp. 702-708, 2011.
37. R. D. Granstein, W. Ding, and H. Ozawa, "Induction of antitumor immunity with epidermal cells pulsed with tumor-derived RNA or intradermal administration of RNA, " Journal of Investigative Dermatology, vol. 114, no. 4, pp. 632-636, 2000.
38. J. A. Wolff, R. W. Malone, P. Williams et al., "Direct gene transfer into mousemuscle in vivo, " Science, vol. 247, no. 4949, pp. 1465-1468, 1990.
39. J. S. Blum, P. A. Wearsch, and P. Cresswell, "Pathways of antigen processing, " Annual Review of Immunology, vol. 31, no. 1, pp. 443-473, 2013.
40. C. Linnemann, M. M. van Buuren, L. Bies et al., "Highthroughput epitope discovery reveals frequent recognition of neo-antigens by CD4+ T cells in human melanoma, " Nature Medicine, vol. 21, pp. 81-85, 2015.
41. S. Janetzki, C. M. Britten, M. Kalos et al., "MIATA-minimal information about T cell assays, " Immunity, vol. 31, no. 4, pp. 527-528, 2009.